Oct. 5 at 6:30 AM
$CADL Here’s a summary table combining fundamentals, pipeline potential, and investor behavior impact on Candel Therapeutics (CADL) share price outlook (2025–2029):
---
📊 Candel Therapeutics (CADL) — 4-Year Forecast Summary
Year Core Fundamentals (Pipeline-Driven Fair Value) Investor Behavior Multiplier (B) Adjusted Price Estimate (USD) Expected Sentiment Phase Key Catalysts / Risks
2025 → 2026 (1 year)
$11.1 0.9× ≈
$10.0 Neutral / Slight Risk-Off FDA meetings for CAN-2409; potential dilution; macro biotech sentiment still cautious
2026 → 2027 (2 years)
$33.4 1.2× ≈
$40.0 Improving / Risk-On Phase Regulatory clarity, partnership or licensing deals, broader institutional interest
2027 → 2028 (3 years)
$66.8 1.6× ≈
$107.0 Biotech Hype Cycle Positive Phase 3/approval events, M&A speculation, strong inflows into biotech ETFs
2028 → 2029 (4 years)
$89.1 1.3× ≈
$116.0 Post-Hype Stabilization Commercial launch, real revenue visibility, possible acquisition or royalties.
